AI Health Index

RapidAI vs Viz.ai (2026)

Verdict

Both sit in the acute neurovascular pathway and both grade A with the AI Health Index on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status, so the regulatory question is settled for both and the choice is about which part of the pathway is failing. Viz.ai is the care coordination answer: it holds the first FDA De Novo authorization for computer aided triage and notification, which created the regulatory category, and its mechanism is mobilizing the treating team the moment a finding lands. RapidAI is the imaging depth answer: its clearances extend past the moment of triage into characterizing and tracking disease over time, and the company positions its perfusion analysis as the only such analysis validated in randomized trials. The index separates them on autonomy, where Viz.ai grades higher, and on deployment model and data residency, where RapidAI does. If the minutes between detection and the team assembling are the failure, start with Viz.ai. If the failure is everything that happens after the first read, start with RapidAI.

The case for RapidAI
  • Depth past the point of triage: the cleared module set covers characterization and longitudinal tracking rather than detection alone, which is the constraint once a stroke program is already fast.
  • RapidAI grades higher than Viz.ai on Deployment Model and Data Residency in this index, which matters where data location or hosting is contractually constrained.
  • The company positions its CT and MR perfusion analysis as the only such analysis clinically validated in randomized controlled trials, a vendor claim worth verifying at source but unusual in this category.
The case for Viz.ai
  • Viz.ai holds the first FDA De Novo authorization for computer aided triage and notification and has built the broadest cleared indication set in imaging AI on top of it.
  • Team mobilization is the mechanism rather than a feature: the product connects the specialists who act, which is the workflow that decides outcomes in large vessel occlusion.
  • Viz.ai grades higher than RapidAI on Autonomy and Oversight Model, Commercial Transparency and Setting and Specialty Coverage in this index.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. RapidAI and Viz.ai are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

Disclosure

Clearance counts, the randomized trial positioning and the reported time savings are vendor published and should be verified against the FDA clearance database before they are relied on in a selection. Neither vendor publishes pricing, and both grade D on Model Supply Chain Disclosure in this index, meaning neither names the model providers or subprocessors behind the product. Both carry a Medicare New Technology Add on Payment pathway on at least one module, which changes the economics and should be confirmed for the specific indication being bought.